These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12194808)

  • 21. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
    Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
    Mostaghel EA; Page ST; Lin DW; Fazli L; Coleman IM; True LD; Knudsen B; Hess DL; Nelson CC; Matsumoto AM; Bremner WJ; Gleave ME; Nelson PS
    Cancer Res; 2007 May; 67(10):5033-41. PubMed ID: 17510436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
    Nishiyama T
    Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
    Taplin ME; Manola J; Oh WK; Kantoff PW; Bubley GJ; Smith M; Barb D; Mantzoros C; Gelmann EP; Balk SP
    BJU Int; 2008 May; 101(9):1084-9. PubMed ID: 18399827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
    J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Goldenberg SL; Lange PH; Sullivan LD
    J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT).
    Cho D; Di Blasio CJ; Rhee AC; Kattan MW
    Urol Oncol; 2003; 21(4):282-91. PubMed ID: 12954499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal treatment for prostate cancer.
    Harris KA; Small EJ
    Expert Opin Investig Drugs; 2001 Mar; 10(3):493-510. PubMed ID: 11227048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of endothelin-1 gene single-nucleotide polymorphisms and haplotypes with risk of hormone refractory prostate cancer.
    Xu D; Wang X; Lou Y
    Pharmazie; 2017 Feb; 72(2):103-106. PubMed ID: 29441862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer.
    Fankhauser M; Tan Y; Macintyre G; Haviv I; Hong MK; Nguyen A; Pedersen JS; Costello AJ; Hovens CM; Corcoran NM
    Clin Cancer Res; 2014 Nov; 20(21):5547-57. PubMed ID: 24771644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of patients with hormone refractory prostate cancer.
    Muthuramalingam SR; Patel K; Protheroe A
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    Sharifi N; Dahut WL; Figg WD
    BJU Int; 2008 Feb; 101(3):271-4. PubMed ID: 17922868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
    Murez T; Basset V; Audenet F; Lebret T; Branchereau J
    Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.